PlentiPlex™ MYD88

Waldenström Lymphoma qPCR Assay

- Sensitive detection of MYD88 L265P mutation
- For discrimination between lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia (LPL/WM) and Non-Hodgkin lymphoma
- Open platform design



PentaBase

PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay is intended for efficient and sensitive detection of the MYD88 L265P mutation. Results can be used for discrimination between lymphoplasmacytic lymphoma/Waldenström macroclobulinamia (LPL/WM) and Non-Hodkin lymphoma. High sensitivity is ensured by incorporation of unique PentaBase INA® technology and PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay is provided as either Ready-to-Use or Dispense Ready versions for minimal hands-on time or cost-efficient analyses.

Results in less than two hours

Based on INA® technology

Ready-to-Use optionality

0.6-0.75% LOD

For more information

Version 1.1

Specifications

Mutations	Product Variants
MYD88 L265P	Ready-to-Use variant pre-dispensed in PCR strip-tubes for minimum hands-on time Dispense Ready variant for cost-efficient bulk analyses
Intended Use	**Input**
Identification of the presence of the MYD88 L265P mutation, to assist in discrimination between Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma	2 x 5-50 ng of human DNA
Limit of Detection	**Result Time**
0.6% in whole blood and 0.75% in FFPE samples	Less than 2 hours
Instrument compatibility[1]	**Specimens**
PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay is designed for open platforms including but not limited to: -Applied Biosystems (7500, 7900, QuanStudio™) -Bio Molecular Systems (Mic[2]) -Bio-Rad (CFX) -Illumina (Eco™) -Qiagen (Rotor-Gene Q) -Roche (LightCycler® 480) -PentaBase (BaseTyper™)	Specimens should be human genomic DNA extracted from Formalin-Fixed Paraffin-Embedded (FFPE) or whole blood samles
	Purification Methods
	Any manual or automatic purification method suitable for purification of genomic DNA from FFPE or whole blood samples
1. Performance evaluation has only been performed on a limited group of instruments. Please refer to the *Instructions For Use* of the specific assays for details regarding instruments used during performance evaluation.	**Minimum Tumour Cell Percentage**
2. Only Dispense Ready variant	20%

PentaBase

PentaBase is a knowledge-based, ISO-certified real-time PCR-focused company founded and managed by researchers in Denmark. We have local *in-house* production of custom oligonucleotides and IVD qPCR assays based on our own proprietary DNA chemistry known as Intercalating Nucleic Acid (INA®). We specialise in development and manufacturing of oligonucleotides and *in vitro* diagnostic assays for real-time PCR with focus on detection of somatic mutations in cancer. For more than 10 years we have created products for researchers and medical professionals exploring new treatments and helping patients worldwide.

CE IVD

Contact us

Petersmindevej 1A,
DK-5000 Odense C

+45 36 96 94 96

info@pentabase.com

www.pentabase.com

Version 1.1